Dark

Check out our API

ALLGF
ALLEGO N.V.
stock OTC

Inactive

Feb 18, 2020

0.8700USD-70.612%(-2.0904)1,500

Pre-market

0.00USD-100.000%(-2.96)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Dec 29, 2020

03:24AM EST Alligator Bioscience recruits new Chief Medical Officer PR Newswire

Dec 28, 2020

05:28AM EST Alligator Bioscience Submits CTA For Mitazalimab Phase II Study OPTIMIZE-1 RTTNews

05:26AM EST Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1 PR Newswire

Dec 10, 2020

02:52AM EST Alligator Bioscience launches ALLIGATOR-FAB(tm) - a novel human antibody library PR Newswire

Dec 4, 2020

03:19AM EST Approved IND for Alligator Bioscience's CD40-targeting antibody mitazalimab PR Newswire

Oct 27, 2020

09:17AM EDT Predicted therapeutic range dose levels reached in ATOR-1017 Phase I PR Newswire

Oct 22, 2020

01:27AM EDT Alligator Bioscience To Focus Resources On Two Proprietary Candidate Drugs, ATOR-1017 And Mitazalimab RTTNews

01:24AM EDT Alligator Bioscience focuses on ATOR-1017 and mitazalimab PR Newswire

Sep 16, 2020

02:41AM EDT Alligator Bioscience Secures Patent Approval For Drug Candidate ATOR-1015 RTTNews

02:40AM EDT Alligator Bioscience receives patent approval for the drug candidate ATOR-1015 PR Newswire

Sep 4, 2020

02:42AM EDT Alligator Bioscience presents positive biomarker data demonstrating proof of PR Newswire

Aug 27, 2020

02:50AM EDT Alligator Bioscience: Encouraging interim safety data in ATOR-1017 clinical PR Newswire

Aug 25, 2020

05:10AM EDT Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day PR Newswire

Jul 13, 2020

07:25AM EDT Alligator Bioscience AB (publ) Interim Report January-June 2020 PR Newswire

Share